< Back to Newsroom

PROCEPT BioRobotics’ AQUABEAM System Recognized with “Best Healthcare Robotics Solution” Award

REDWOOD SHORES, Calif., June 19, 2018 – PROCEPT BioRobotics today announced that it has been selected as the winner of the “Best Healthcare Robotics Solution” award from MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market today.

The winning solution, PROCEPT BioRobotics’ AquaBeam System, is the world’s first surgical robot providing autonomous tissue removal for the safe and effective treatment of benign prostatic hyperplasia (BPH), or enlarged prostate, independent of prostate anatomy or surgeon experience.

“We are honored to accept this award and thank MedTech Breakthrough for recognizing the importance of surgical robotics in healthcare,” stated Nikolai Aljuri, Ph.D., PROCEPT BioRobotics chief executive officer and founder. “At PROCEPT, we approach every product with both the patient and surgeon in mind. The AquaBeam System is clinically proven to treat BPH through a combination of multi-dimensional imaging for improved surgeon decision-making with robotics for autonomous and precise tissue resection with a heat-free waterjet. This ensures patients a significant improvement to quality of life with a reduced risk of sexual side effects.”

BPH is a highly prevalent condition affecting approximately 50 percent of men age 60 or older and 90 percent of men age 85 or older. In the United States, there are over 12 million men being actively managed for their condition, of which two million have failed medical management and are looking for alternative treatment options.

“Surgical robotics is certainly one of the most exciting fields in healthcare, and we are pleased to recognize PROCEPT BioRobotics for its innovation and leadership in this area,” said James Johnson, managing director, MedTech Breakthrough. “The AquaBeam System addresses a large unmet need – providing an effective treatment option for patients suffering from BPH. We congratulate the entire PROCEPT BioRobotics team on their 2018 MedTech Breakthrough Award recognition.”

About MedTech Breakthrough
The MedTech Breakthrough Awards program, part of the Tech Breakthrough Awards organization, is devoted to honoring excellence in medical and health related technology companies, products and people. MedTech Breakthrough provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. This year’s program attracted more than 3,000 nominations from over 12 different countries throughout the world. For more information visit www.MedTechBreakthrough.com.

About PROCEPT BioRobotics Corporation
Based in Silicon Valley, PROCEPT BioRobotics is a privately-held surgical robotics company enabling better patient care by developing transformative solutions in urology. The company’s first offering, Aquablation therapy, delivered by the AquaBeam System, is the first FDA granted surgical robot providing autonomous tissue removal for the treatment of BPH. Aquablation therapy combines the clarity of real-time, multi-dimensional imaging, autonomous robotics and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue for the treatment of lower urinary tract symptoms (LUTS) caused by BPH. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size or surgeon experience. The AquaBeam System is commercially available in the United States, Canada, Australia, New Zealand and select European markets.  http://www.PROCEPT-BioRobotics.com